Pharmacopeia

CWP-0163

METOCLOPRAMIDE

Gastrointestinal · Level 3

Core pharmacology

Class Group

Anti-emetic

Dopamine Antagonist

Indications Uses

1. Prokinetic
2. Antiemetic
3. Migraine
4. Reflux oesophagitis

Presentation

PO/IV

Physiological effects

CVS: Hypotension after IV; Dysrhythmias and QTc

GIT
1. Selective stimulation of gastric muscarinic receptors
- Coordinated GIT contraction (accelerates gastric emptying)
- Increased amplitude and frequency of Longitudinal muscle contraction
- Lowers threshold for peristaltic reflex to occur
2. Direct action on smooth muscle to increase tone (including increased LOS)
3. Reduces intestinal muscle fatigue

CNS
- Neuroleptic effects
- Extrapyramidal effects
- Increase prolactin

GU- Increased uterine peristalsis

Protein binding

20% PB

Introduction

Antiemetic and prokinetic dopamine D2 antagonist.

Mechanism of action

Peripheral D2 antagonism, augmentation of peripheral cholinergic responses and direct smooth-muscle effects increase gastrointestinal motility. Central D2 blockade raises the vomiting threshold at the chemoreceptor trigger zone, and reduced visceral afferent input contributes to antiemesis.

Adverse Effects Toxicity

Drowsiness, dizziness and faintness. Bowel disturbance. Extrapyramidal reactions including akathisia and oculogyric crises. Neuroleptic malignant syndrome. Hyperprolactinaemia.

Absorption

Rapid oral absorption. Oral bioavailability 32-97% because of first-pass sulfate conjugation.

Volume of distribution

2.2-3.4 L/kg.

Metabolism

Primarily hepatic metabolism. The major metabolite is a sulfate derivative.

Excretion

80% of an oral dose is excreted in urine within 24 hours. 20% of the urinary amount is unchanged, with the remainder as conjugated parent drug or metabolites.

Half-life

2.6-5 hours.